Physician profile
Paul B Ramilo
NPI 1821045501
$10,341.90
in general payments reported to CMS, 2019-2025
22 companies · $767 in 2025
The $767 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $1,691 · 2021: $1,558 · 2022: $1,841 · 2023: $1,555 · 2024: $1,478 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,628 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,628.35 |
| Education | $171.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,223.01 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,600.21 | 2019-2025 | Veklury, Biktarvy |
| Melinta Therapeutics, LLC | $1,114.07 | 2019-2024 | Kimyrsa, Vabomere, Rezzayo |
| Merck Sharp & Dohme LLC | $902.56 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Theratechnologies INC. | $819.28 | 2019-2025 | Egrifta, Trogarzo |
| Abbvie INC. | $666.33 | 2021-2025 | |
| Janssen Biotech, INC. | $564.86 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $528.60 | 2019-2023 | Mytesi |
| Shionogi INC | $397.71 | 2022-2025 | Fetroja |
| Insmed, INC. | $302.70 | 2019-2024 | Arikayce |
| Janssen Products, LP | $263.98 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $206.53 | 2019-2025 | Nuzyra |
| Allergan, INC. | $202.92 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $120.47 | 2022-2024 | Xerava |
| Takeda Pharmaceuticals U.S.A., INC. | $114.35 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $88.25 | 2019-2024 | Cresemba |
| Mylan Institutional INC. | $65.57 | 2019 | |
| Aimmune Therapeutics, INC. | $61.32 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $36.53 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $23.29 | 2024 | Rebyota |
| Vyera Pharmaceuticals, LLC | $20.31 | 2022 | |
| Dynavax Technologies Corporation | $19.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ramilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.